These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36471629)

  • 41. Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liang Y; Xu H; Liu F; Li L; Lin C; Zhang Y; Wang N; Wang L
    Front Oncol; 2024; 14():1281645. PubMed ID: 38887231
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
    Kfoury M; Najean M; Lappara A; Voisin AL; Champiat S; Michot JM; Laghouati S; Robert C; Besse B; Soria JC; Lambotte O; Massard C; Marabelle A; Texier M
    Cancer Treat Rev; 2022 Nov; 110():102452. PubMed ID: 35998515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients].
    Cui S; Ge X; Li X
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):257-264. PubMed ID: 37183640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
    Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
    Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
    Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
    Front Immunol; 2022; 13():879900. PubMed ID: 35924238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study.
    Zhang Y; Wang X; Li Y; Hong Y; Zhao Q; Ye Z
    Front Immunol; 2023; 14():1141148. PubMed ID: 37033935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease.
    Lopez-Olivo MA; Kachira JJ; Abdel-Wahab N; Pundole X; Aldrich JD; Carey P; Khan M; Geng Y; Pratt G; Suarez-Almazor ME
    Eur J Cancer; 2024 Aug; 207():114148. PubMed ID: 38834015
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    An Y; Wu Z; Wang N; Yang Z; Li Y; Xu B; Sun M
    J Transl Med; 2020 Jun; 18(1):235. PubMed ID: 32532255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic disease and adverse events from immune checkpoint inhibitors.
    Leiter A; Carroll E; De Alwis S; Brooks D; Shimol JB; Eisenberg E; Wisnivesky JP; Galsky MD; Gallagher EJ
    Eur J Endocrinol; 2021 Jun; 184(6):857-865. PubMed ID: 34552304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H
    Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
    Liu X; Li S; Ke L; Cui H
    BMC Cancer; 2024 Apr; 24(1):490. PubMed ID: 38632528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
    Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
    Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
    van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
    Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
    Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
    Front Immunol; 2022; 13():987568. PubMed ID: 36159840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis.
    Xu H; Xu X; Ge W; Lei J; Cao D
    Ther Adv Med Oncol; 2020; 12():1758835920980546. PubMed ID: 33425028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.